Life Cycle Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Life Cycle Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.84M	Buy	+143,692	New	+$7.57M	0.04%	149

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Life Cycle Investment Partners's CRSP Position: Q2 2026 in Review

Life Cycle Investment Partners opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 143,692 shares worth $7.84M. The stake represents 0.04% of the portfolio and ranks #149 among its holdings.

521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Life Cycle Investment Partners held 143,692 shares of CRISPR Therapeutics worth $7.84M as of Q2 2026.
CRISPR Therapeutics was a new Life Cycle Investment Partners position in Q2 2026.
CRISPR Therapeutics made up 0.04% of Life Cycle Investment Partners's portfolio in Q2 2026, its #149 holding.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Life Cycle Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.